Challenges posed to the European pharmaceutical regulatory system by highly personalized medicines

British Journal of Clinical Pharmacology

Volumn 77, Issue 3, 2014, Pages 421-426

  Johnston, John D ^a   Feldschreiber, Peter ^b  

^a Law ^*  (United Kingdom)

^b University of Law   (United Kingdom)

Author keywords

antisense oligo nucleotide; Europe; highly personalized medicine; pharmaceutical regulation; RNA

Indexed keywords

ANTISENSE OLIGO-NUCLEOTIDE; EUROPE; HIGHLY PERSONALIZED MEDICINE; PHARMACEUTICAL REGULATION; RNA;

DRUG INDUSTRY; EUROPE; GENE EXPRESSION REGULATION; HUMANS; INDIVIDUALIZED MEDICINE; LEGISLATION, DRUG; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; PATENTS AS TOPIC; POLICY MAKING; RNA;

EID: 84894484051     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12173     Document Type: Article

References (7)

1. Kole R, Krainer AR, Altman S,. RNA therapeutics: beyond RNA interference and anti-sense oligo-nucleotides. Nat Rev Drug Discov 2012; 11: 125-140.
2. Burnett JC, Rossi JJ,. RNA-based therapeutics-current progress and future prospects. Chem Biol 2012; 19: 60-71.
3. Far RKK, Nedbal W, Sczakiel G,. Concepts to automate the theoretical design of effective anti-sense oligo-nucleotides. Bioinformatics 2001; 17: 1058-1061.
4. Chan JHP, Lim S, Wong WSF,. Anti-sense oligo-nucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006; 33: 533-540.
5. Juliano R, Bauman J, Kang H, Ming X,. Biological barriers to therapy with anti-sense and siRNA oligo-nucleotides. Mol Pharm 2009; 6: 686-695.
6. Aartsma-Rus A, Laura V, Marscha H, Janson AAM, Heemskerk H, de Winter CL, de Kimpe S, van Deutekom JCT, 't Hoen PAC, van Ommen GJB,. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 2009; 17: 548-553.
7. Aartsma-Rus A,. The risks of therapeutic misconception and individual patient (n=1) 'trials' in rare diseases such as Duchenne dystrophy. Neuromuscul Disord 2011; 21: 13-15